Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccines and Therapeutic Approaches in Dermatological Diseases
share announcement

Vaccines and Therapeutic Approaches in Dermatological Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 3323

Special Issue Editors

Prof. Dr. Thilo Gambichler

E-Mail Website
Guest Editor
1. Department of Dermatology, Dortmund Hospital, University Witten/Herdecke, 44137 Dortmund, Germany
2. Department of Dermatology and Phlebology, Christian Hospital Unna, 59423 Unna, Germany
Interests: dermato-oncology; melanoma; immunotherapy; vaccination side effects; skin cancer; skin; psoriasis; clinical dermatology; basal cell carcinoma; squamous cell carcinoma; Merkel cell carcinoma
Special Issues, Collections and Topics in MDPI journals
Dr. Nessr Abu Rached

E-Mail Website
Guest Editor Assistant
1. International Centre for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
2. Skin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
Interests: hidradenitis suppurativa; inflammation; hormones; Merkel cell carcinoma; melanoma; endocrinology; skin cancer; obesity

Special Issue Information

Dear Colleagues,

Vaccines are being investigated to treat and prevent skin diseases. Vaccines against solid tumors and skin cancer have recently seen increased development. In allergology, vaccines are also successfully used for hyposensitisation against certain allergens. Noninvasive dermal delivery systems make it easy to apply vaccines to different areas of the body. This method can impact clinical treatment due to many skin diseases with therapeutic targets. Currently, most clinical trials for therapies for skin disorders are conducted through intradermal injection. Combining noninvasive delivery techniques with specific vaccine formulation approaches can improve dermal delivery and achieve better therapeutic results. Recent efforts have been made to overcome the skin's barrier function using various smart delivery systems. By addressing these aspects and combining them with a deeper understanding of cell biology, we can improve the design of bioengineered materials to navigate the skin and enhance preventive and therapeutic outcomes.

This Special Issue aims to advance this field by providing a better understanding of how to safely and effectively deliver various vaccine types to target cells. The translational value of preclinical studies can be increased using human-relevant models or studies on human skin explants, tissue-engineered skin models, and human-based tissues grafted onto mice are welcome. We encourage all articles and reviews.

Prof. Dr. Thilo Gambichler
Guest Editor

Dr. Nessr Abu Rached
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccinations
  • vaccines
  • dermatology
  • tumor therapy
  • immune system
  • side effects
  • skin reactions
  • virus vaccines
  • virus
  • bacteria
  • COVID-19 vaccines
  • mRNA
  • vasculitis
  • angioedema
  • anaphylaxis
  • thrombocytopenia
  • B cells
  • T cells
  • vaccination complication
  • safety
  • target structures

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2450 KiB  
Article
UL56 Is Essential for Herpes Simplex Virus-1 Virulence In Vivo but Is Dispensable for Induction of Host-Protective Immunity
by Nopprarat Tongmuang, Meera Krishnan, Viv Connor, Colin Crump and Liselotte E. Jensen
Vaccines 2024, 12(8), 837; https://doi.org/10.3390/vaccines12080837 - 25 Jul 2024
Viewed by 1094
Abstract
Herpes simplex virus-1 (HSV-1) is common and can cause significant disease in humans. Unfortunately, efforts to develop effective vaccines against HSV-1 have so far failed. A detailed understanding of how the virus infects its host and how the host mounts potent immune responses [...] Read more.
Herpes simplex virus-1 (HSV-1) is common and can cause significant disease in humans. Unfortunately, efforts to develop effective vaccines against HSV-1 have so far failed. A detailed understanding of how the virus infects its host and how the host mounts potent immune responses against the virus may inform new vaccine approaches. Here, using a zosteriform mouse model, we examined how the HSV-1 gene UL56 affects the ability of the virus to cause morbidity and generate protective immunity. A UL56 deletion mutant, ΔUL56, was derived from the wild-type HSV-1 strain SC16, alongside a revertant strain in which UL56 was reintroduced in ΔUL56. In vitro, the three virus strains replicated in a similar manner; however, in vivo, only the wild type and the revertant strains caused shingles-like skin lesions and death. Mice previously infected with ΔUL56 became resistant to a lethal challenge with the wild-type SC16. The protective immunity induced by ΔUL56 was independent of IL-1, IL-33, and IL-36 signaling through IL-1RAP. Both skin and intramuscular ΔUL56 inoculation generated protective immunity against a lethal SC16 challenge. After 6 months, female mice remained resistant to infection, while male mice exhibited signs of declining protection. Our data demonstrate that UL56 is important for the ability of HSV-1 to spread within the infected host and that a ∆UL56 strain elicits an effective immune response against HSV-1 despite this loss of virulence. These findings may guide further HSV-1 vaccine development. Full article
(This article belongs to the Special Issue Vaccines and Therapeutic Approaches in Dermatological Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 1036 KiB  
Review
Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update
by Thilo Gambichler, David Schrama, Riina Käpynen, Sera S. Weyer-Fahlbusch, Jürgen C. Becker, Laura Susok, Florian Kreppel and Nessr Abu Rached
Vaccines 2024, 12(5), 533; https://doi.org/10.3390/vaccines12050533 - 13 May 2024
Cited by 2 | Viewed by 1404
Abstract
Merkel cell carcinoma is a rare, aggressive skin cancer that mainly occurs in elderly and immunocompromised patients. Due to the success of immune checkpoint inhibition in MCC, the importance of immunotherapy and vaccines in MCC has increased in recent years. In this article, [...] Read more.
Merkel cell carcinoma is a rare, aggressive skin cancer that mainly occurs in elderly and immunocompromised patients. Due to the success of immune checkpoint inhibition in MCC, the importance of immunotherapy and vaccines in MCC has increased in recent years. In this article, we aim to present the current progress and perspectives in the development of vaccines for this disease. Here, we summarize and discuss the current literature and ongoing clinical trials investigating vaccines against MCC. We identified 10 articles through a PubMed search investigating a vaccine against MCC. From the international clinical trial database Clinical.Trials.gov, we identified nine studies on vaccines for the management of MCC, of which seven are actively recruiting. Most of the identified studies investigating a vaccine against MCC are preclinical or phase 1/2 trials. The vaccine principles mainly included DNA- and (synthetic) peptide-based vaccines, but RNA-based vaccines, oncolytic viruses, and the combination of vaccines and immunotherapy are also under investigation for the treatment of MCC. Although the management of MCC is changing, when compared to times before the approval of immune checkpoint inhibitors, it will still take some time before the first MCC vaccine is ready for approval. Full article
(This article belongs to the Special Issue Vaccines and Therapeutic Approaches in Dermatological Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop